Washington, Sept 25 ANI: A scientists from the UC San Diego
Stroke Center has warned that
doctors should not lose a single moment in
giving intravenous thrombolysis
treatment for acute ischemic
stroke.Patrick Lyden, M.D., professor of neurosciences, has cautioned that that an earlier study on the efficacy of the
treatment after acute
stroke should not be interpreted to mean that such therapy can be withheld for hours or even minutes. "The risk of withholding such
treatment from
patients with acute
stroke greatly exceeds the risk of
giving it. The potential for reversing the disabling side effects of
stroke declines with every passing minute," said Lyden. "."Lyden's warning comes in line with the study, "Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke" by Werner Hacke, M.D. et al, that reported the findings from the European Cooperative Acute
Stroke Study III ECASS III. The
design of this study was quite similar to that of the original National
Institute of Neurological Disorders and
Stroke NINDS trial of recombinant tissue plasminogen activator rt-PA for acute
stroke. It was a pivotal trial that Lyden helped lead that showed the first proven therapy for
stroke. The important exception in the ECASS III trial is that the
window of therapy was expanded to a period of three to four and a half hours, compared to under three hours in the NINDS trial.Lydens aid that the biggest drawback of the BCASS III
data is that some may take a slower approach to treating acute
stroke."Nothing could be more wrong. As we look back on the past decade of thrombolytic therapy for
stroke, it is very clear that our focus must remain on the
door-to-needle time. Every minute matters during a
stroke," said Lyden. ANI